Literature DB >> 8387282

Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma.

K Kitamura1, K Kangawa, M Kawamoto, Y Ichiki, S Nakamura, H Matsuo, T Eto.   

Abstract

A novel hypotensive peptide was discovered in human pheochromocytoma by monitoring the elevating activity of platelet cAMP. Since this peptide is abundant in normal adrenal medulla as well as in pheochromocytoma tissue arising from adrenal medulla, it was designated "adrenomedullin". The peptide, consisting of 52 amino acids, has one intramolecular disulfide bond and shows slight homology with calcitonin gene related peptide. It was found to elicit a potent and long lasting hypotensive effect. The peptide circulates in blood in a considerable concentration, but it was not found in brain. These data suggest that adrenomedullin is a new hormone participating in blood pressure control. Occurrence of adrenomedullin indicates the possible existence of a novel system for circulation control.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387282     DOI: 10.1006/bbrc.1993.1451

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  302 in total

Review 1.  Calcitonin and calcitonin receptors: bone and beyond.

Authors:  M Pondel
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

2.  Characterization of receptors for calcitonin gene-related peptide and adrenomedullin on the guinea-pig vas deferens.

Authors:  D R Poyner; G M Taylor; A E Tomlinson; A G Richardson; D M Smith
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

3.  CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.

Authors:  P Hasbak; A Sams; S Schifter; J Longmore; L Edvinsson
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Hypertension in patients with pheochromocytoma.

Authors:  N N Hanna; D E Kenady
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

5.  Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: role of adrenomedullin and adrenomedullin binding protein-1.

Authors:  Shaolong Yang; Mian Zhou; Irshad H Chaudry; Ping Wang
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

6.  Attenuation of renal ischemia and reperfusion injury by human adrenomedullin and its binding protein.

Authors:  Kavin G Shah; Derry Rajan; Asha Jacob; Rongqian Wu; Kambhampaty Krishnasastry; Jeffrey Nicastro; Ernesto P Molmenti; Gene F Coppa; Ping Wang
Journal:  J Surg Res       Date:  2010-04-24       Impact factor: 2.192

7.  Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning.

Authors:  R M Hu; Z G Han; H D Song; Y D Peng; Q H Huang; S X Ren; Y J Gu; C H Huang; Y B Li; C L Jiang; G Fu; Q H Zhang; B W Gu; M Dai; Y F Mao; G F Gao; R Rong; M Ye; J Zhou; S H Xu; J Gu; J X Shi; W R Jin; C K Zhang; T M Wu; G Y Huang; Z Chen; M D Chen; J L Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

8.  Adrenomedullin protects from experimental autoimmune encephalomyelitis at multiple levels.

Authors:  Marta Pedreño; Maria Morell; Gema Robledo; Luciana Souza-Moreira; Irene Forte-Lago; Marta Caro; Francisco O'Valle; Doina Ganea; Elena Gonzalez-Rey
Journal:  Brain Behav Immun       Date:  2013-12-07       Impact factor: 7.217

9.  Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

10.  Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure.

Authors:  T Ishimitsu; T Nishikimi; Y Saito; K Kitamura; T Eto; K Kangawa; H Matsuo; T Omae; H Matsuoka
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.